A microbiome approach to address NAFLD and intrahepatic cholestasis in pregnancy

MetaboGen is active in the field of live biotherapeutic products and on the study of liver diseases. We discussed their approach with Sara Malcus, CEO of the company.

Recently, the European Pharmacopoeia Commission has expressed its quality requirements on the so called live biotherapeutic products (LBPs) for human use.

Among the European biotech companies active in this field, the swedish MetaboGen is addressing the human microbiota, with a particular focus on the production of butyrate and on the Non-Alcoholic Fatty Liver Disease (NAFLD).

«We think that the microbiome can make the difference – says Sara Malcus, CEO of MetaboGen. We are addressing the liver function and the effects of the microbiome in diseases related to the liver and we have activated a study on intrahepatic cholestasis in pregnancy together with Ferring Pharmaceuticals. We are really excited about the future of the microbiome – concludes Malcus – and we are really looking forward to seeing the developments in this field.»